Wayne R. Godfrey

Therapeutics Clinical Research — United States

Medicine · Health Sciences

20h-index5.6kcitations52works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(20), Chronic Lymphocytic Leukemia Research(18), CAR-T cell therapy research(17), Immunotherapy and Immune Responses(15), T-cell and B-cell Immunology(10)

Publications52 total

Abstract B04: Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors
Cancer Immunology Research·2022· 5 cited
1326 A bifunctional tumor activated immunomodulator (TRACIr) targeting PD-L1 And CD28 Is a potent enhancer of T cell-mediated anti-tumor activity
Regular and Young Investigator Award Abstracts·2022Open Access
1325 Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T Cell engager for treatment of metastatic castration-resistant prostate cancer
Regular and Young Investigator Award Abstracts·2022· 8 citedOpen Access
1123 Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors
Regular and Young Investigator Award Abstracts·2022· 3 citedOpen Access
841P IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
Annals of Oncology·2021· 1 cited
Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Transplantation and Cellular Therapy·2021· 4 cited
Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Blood·2020· 105 cited
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
Blood·2020· 9 cited
Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323).
Journal of Clinical Oncology·2020· 1 cited
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Blood Advances·2016· 18 citedOpen Access
Mature Follow-up from a Phase-2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Acta Haematologica Polonica·2015· 8 cited
Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).
Journal of Clinical Oncology·2015· 6 cited
Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study.
Journal of Clinical Oncology·2015· 6 cited
Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results
Blood·2014· 13 cited
Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Blood·2014· 21 cited
Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Journal of Clinical Oncology·2014· 7 cited
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Blood·2014· 206 citedOpen Access
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Blood·2014· 247 citedOpen Access
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
New England Journal of Medicine·2014· 1.0k citedOpen Access
Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Blood·2013· 14 cited
page 1 of 3Next →

Frequent Co-authors

Nina D. Wagner‐Johnston(15), Ian W. Flinn(15), Sven de Vos(14), Brad S. Kahl(10), Steven Coutré(10), John P. Leonard(10), Leanne Holes(9), Gilles Salles(9), Ajay K. Gopal(8), Roger Dansey(8), David M. Johnson(8), Christopher R. Flowers(7), Pier Luigi Zinzani(7), Richard R. Furman(7), Stephen J. Schuster(6), Wojciech Jurczak(6), Andreas Viardot(6), Andrew Davies(6), Martin Dreyling(6), Bruce R. Blazar(6)